Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02436356
Other study ID # 141125
Secondary ID UL1TR000445
Status Terminated
Phase N/A
First received
Last updated
Start date June 30, 2015
Est. completion date November 8, 2018

Study information

Verified date October 2020
Source Vanderbilt University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to determine whether two new, non-X-ray techniques can discriminate between high-energy fractures of normal bone (trauma) and low-energy fractures (fragility) of osteoporotic bone. The current gold-standard for assessing fracture risk areal bone mineral density (aBMD) by dual energy X-ray absorptiometry (DXA) is not particularly effective at identifying individuals who are at risk of suffering a fracture. Yet, there is a growing population of diabetics and elderly individuals prone to fractures. In effect, the age-related and diabetes-related increase in fracture risk is independent of a person's aBMD. These findings stress the urgency in developing diagnostic tools that can improve fracture risk prediction so that patients can be treated with the appropriate anti-fracture therapies.


Recruitment information / eligibility

Status Terminated
Enrollment 48
Est. completion date November 8, 2018
Est. primary completion date May 23, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion/exclusion criteria for patients with a high-energy or fragility fracture requiring operative fixation (Arm 1) Number of patients in Arm#1= 60 patients Inclusion criteria: 1. Patients who are 18 years of age or older. This age range accounts for 60% of all distal radius fractures seen at Vanderbilt University Medical Center. 2. Patients who have sustained a low or high energy distal radius fracture that involves the metaphysis and requires open reduction internal fixation using volar plating. 3. English speaking due to feasibility of employing study personnel to deliver and assess study intervention. Exclusion criteria: 1. Patients who have known risk factors of pathologic fractures (e.g. bone metastasis) 2. Patients who have or are receiving treatment for osteoporosis (e.g. bisphosphonate) lasted longer than 5 years 3. Patients who have Type 1 diabetes 4. Patients who have other bone disease (e.g., osteogenesis imperfecta, Paget's disease, thyroid disease, Vitamin D deficiency, hyperparathyroidism) 5. Patients that have a history of cancer, abnormal serum calcium, or chronic steroid use 6. Patients that would not be able to have a DXA scan (weight >350lbs, hardware in hips, patients that have lap band device) 7. Patients who are pregnant or who think they may be pregnant 8. Patients that have a medical contraindication to MRI (if patients are undergoing a study MRI) 9. Patients who have concurrent, bilateral upper extremity fractures where hardware or casting may affect study scan measurements 10. Patients who have distal radial shaft fractures Exclusion criteria 1-5 are included because the goal of the study is to demonstrate whether new bone measurements differentiate normal bone from fragile bone. These exclusion criteria eliminate confounding factors that affect fracture resistance of bone in ways that are independent of osteoporosis. Exclusion criteria 6-8 are practical since DXA/MRI scans cannot accommodate all people. Inclusion/exclusion criteria for patients with no fracture (Arm 2) Number of patients in Arm#2= 40 patients Inclusion criteria: 1. Patients who are 18 years of age or older. 2. Patients who have no history of fracture or family history of pathologic fracture 3. English speaking due to feasibility of employing study personnel to deliver and assess study intervention. Exclusion criteria: 1. Patients who are taking medication to treat osteoporosis (e.g. bisphosphonate) 2. Patients who have or are receiving treatment for osteoporosis (e.g. bisphosphonate) lasted longer than 5 years 3. Patients who have Type 1 diabetes 4. Patients who have other bone disease (e.g., osteogenesis imperfecta, Paget's disease, thyroid disease, Vitamin D deficiency, hyperparathyroidism). 5. Patients that have a history of cancer, abnormal serum calcium, or chronic steroid use. 6. Patients that would not be able to have a DXA scan (weight >350lbs, hardware in hips, patients that have lap band device) 7. Patients who are pregnant or who think they may be pregnant. 8. Patients that have a medical contraindication to MRI. Exclusion criteria 1-5 are included because the goal of the study is to demonstrate whether new bone measurements differentiate normal bone from fragile bone. These exclusion criteria eliminate confounding factors that affect fracture resistance of bone in ways that are independent of osteoporosis. Exclusion criteria 6- 8 are practical since DXA/MRI scans cannot accommodate all people. Inclusion/exclusion criteria for patients with a high-energy or fragility fracture requiring nonoperative treatment (Arm 3) Number of patients in Arm#3= up to 10 patients Inclusion criteria: 1. Patients who are 18 years of age or older. This age range accounts for 60% of all distal radius fractures seen at Vanderbilt University Medical Center. 2. Patients who have sustained a low or high energy distal radius fracture that requires nonoperative treatment 3. English speaking due to feasibility of employing study personnel to deliver and assess study intervention. Exclusion criteria: 1. Patients who have known risk factors of pathologic fractures (e.g. bone metastasis) 2. Patients who have or are receiving treatment for osteoporosis (e.g. bisphosphonate) lasted longer than 5 years 3. Patients who have Type 1 diabetes 4. Patients who have other bone disease (e.g., osteogenesis imperfecta, Paget's disease, thyroid disease, Vitamin D deficiency, hyperparathyroidism) 5. Patients that have a history of cancer, abnormal serum calcium, or chronic steroid use 6. Patients that would not be able to have a DXA scan (weight >350lbs, hardware in hips, patients that have lap band device) 7. Patients who are pregnant or who think they may be pregnant 8. Patients that have a medical contraindication to MRI (if patients are undergoing a study MRI) 9. Patients who have concurrent, bilateral upper extremity fractures where hardware or casting may affect study scan measurements Exclusion criteria 1-5 are included because the goal of the study is to demonstrate whether new bone measurements differentiate normal bone from fragile bone. These exclusion criteria eliminate confounding factors that affect fracture resistance of bone in ways that are independent of osteoporosis. Exclusion criteria 6-8 are practical since DXA/MRI scans cannot accommodate all people.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Osteoprobe-Reference Point Indentation (RPI)
Diagnostic tool used for bone indentation to measure the ability of the tissue to resist microindentation (bone mineral strength).
Radiation:
Dual-energy X-ray absorptiometry (DXA) Scans
Assessment of Fracture Risk
MRI
Determines bound water and pore water of bone.

Locations

Country Name City State
United States Vanderbilt Univeristy Medical Center Nashville Tennessee

Sponsors (3)

Lead Sponsor Collaborator
Vanderbilt University Medical Center ActiveLife Scientific, National Center for Advancing Translational Science (NCATS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Osteoprobe Measurements Bone Material Strength index (BMSi)
By engaging the bone at 10 N and then delivering a single impact force of ~40 N, the OsteoProbe records the maximum penetration depth of conical-spherical tip into cortical bone. This indentation distance increase (IDI) is indexed to the IDI acquired from a reference material immediately after the bone IDI measurements, such that the OsteoProbe-based measurement known as bone material strength index (BMSi) is 100 times IDI of reference material divided by IDI of the patient's bone. A lower BMSi measurement is the result of a higher indentation distance into the bone. For statistical analysis, we used the mean of the 10 BMSi measurements per case.
Within a week before or after surgery to repair distal radius fracture
Primary MRI Scan Measurements Bound Water Fraction Within a week before or after surgery to repair distal radius fracture
Primary MRI Scan Measurements Pore Water Fraction Within a week before or after surgery to repair distal radius fracture
Primary DXA Scan Measurements Bone Mineral Density Within a week before or after surgery to repair distal radius fracture
Primary DXA Scan Measurements Bone Mineral Content Within a week before or after surgery to repair distal radius fracture
Primary DXA Scan Measurements A T-score is the number of standard deviations (SD) below (negative value) or above (positive value) the mean BMD (bone mineral density) for a healthy population. A person with T-score below -2.5 is considered to have osteoporosis. Within a week before or after surgery to repair distal radius fracture
Secondary Patient-reported Measurements DASH (Disabilities of the Arm, Shoulder, and Hand) is a 30-item self-report questionnaire designed to assess musculoskeletal disorders of the upper limbs. The score ranges from 0 (no disability) to 100 (most severe disability). A higher scores indicate a greater level of disability and severity, whereas, lower scores indicate a lower level of disability. Baseline/One-Time Completion and Post-op/-treatment: 3, 6, and 12 weeks
Secondary Patient-reported Measurements PRWE (Patient-rated wrist evaluation) is a 15-item survey designed to measure wrist pain and disability in activities of daily living. The PRWE consists of a pain subscale and a function subscale. The pain subscale contains 5 items, each rated 0 (no pain) to 10 (worst pain ever). The pain subscale is calculated by adding all 5 item scores together (minimum score: 0, maximum score: 50). A lower score indicates a lower pain level. The function subscale contains 10 items, each rated 0 (no difficulty) to 10 (unable to do). The function subscale is calculated by adding all 10 item scores together and dividing by 2 (minimum score: 0, maximum score: 100). A lower score indicates a lower disability level. The total PRWE score is calculated by adding the pain and function subscales together. The total PRWE score ranges from 0 (best score) to 100 (worst score). The lower the score the better the outcome. Baseline and Post-op/-treatment: 3, 6, and 12 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06287502 - Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis N/A
Completed NCT03822078 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women Phase 1
Recruiting NCT05845021 - Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty N/A
Completed NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) Phase 3
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04736693 - Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
Not yet recruiting NCT06431867 - Primary Care Management of Osteoporosis in Older Women
Completed NCT02922478 - Role of Comorbidities in Chronic Heart Failure Study
Recruiting NCT02635022 - Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
Recruiting NCT02616627 - Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
Active, not recruiting NCT02617303 - Prevention of Falls and Its Consequences in Elderly People N/A
Completed NCT02566655 - Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis Phase 1
Completed NCT02559648 - Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis Phase 2
Not yet recruiting NCT02223572 - Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture N/A
Completed NCT03420716 - Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women N/A
Not yet recruiting NCT01854086 - Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday N/A
Completed NCT02003716 - DeFRA Questionnaire as an Anamnestic Form N/A
Unknown status NCT01913834 - Nasally and sc Administered Teriparatide in Healthy Volunteers Phase 1
Completed NCT01694784 - Understanding and Discouraging Overuse of Potentially Harmful Screening Tests N/A
Completed NCT02143674 - Muscle Strengthening Exercises and Global Stretching in Elderly N/A